Growth FailureNCT04565314
ELICIT 2.0: Pilot Study of the Effect of Maternal Protein Supplementation During Lactation on Childhood Growth
A study testing Plumpy'Mum in people with Growth Failure and Stunting, run by University of Virginia at 1 site in Tanzania.
Trial summary
Haydom Global Health Research Center in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. The region around Haydom is agricultural (predominantly maize-based), is resource-poor and has a high degree of stunting among local infants-with 70%… Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Growth Failure, Stunting, Malnutrition
- What is being tested?
- Plumpy'Mum
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteTanzania
- Study dates
- 12 Nov 2019to 1 Aug 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Maternal age >/= 18 years
- Current pregnancy or infant </= 3 months
Who cannot join
- Maternal inability to adhere to protocol
- Multiple gestation
- Significant birth defect
- Maternal allergy to peanut, milk or soy
- Lack of breast feeding at enrollment (and lack of intention to continue breast feeding at time of enrollment
Trial locations and contacts
1 site in 1 country.
About this study
Haydom Global Health Research Center in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. The region around Haydom is agricultural (predominantly maize-based), is resource-poor and has a high degree of stunting among local infants-with 70% stunting by 18 months in the MAL-ED study and 50% in the ELICIT study (for Early Life Interventions for Childhood Growth and Development In Tanzania). While the causes of this stunting are multifactorial, a potential contributor is early-life nutritional deficiencies, including inadequate dietary protein.
One likely source of low protein delivery to infants is from low intake among area mothers during lactation, with potential effects on breast milk protein content and child weight gain. The current study is a pilot study assessing our study team's ability to successfully deliver protein-containing food products (a balanced-energy protein supplement) to lactating mother is in the area and assessing whether consumption of these food products improves childhood growth in the 1st year of life. This is a pilot study because of the potential difficulties in distributing these products on a large scale for daily consumption. As such, we aim to demonstrate an effective distribution network, a means of assessing adherence, and measuring endpoints while gathering knowledge regarding community acceptance. The current pilot project will evaluate the effectiveness of distribution and adherence on approximately 100 mother/child dyads. If effective, a future project could involve a large enough sample to be powered to detect reasonable changes in linear growth. .
So, while the current proposal is not adequately powered to prove a hypothesis, the hypothesis underlying the study design is that daily protein supplementation delivered as a balanced protein product (Plumpy'mum) to lactating mothers for 3 months during the period from 0-6 months post-natal life will result in an increase in infant length-for-age Z-score (LAZ) by end of treatment. LAZ will be compared to controls from prior studies in the area.
Read the detailed description
In severely under-resourced areas of the world, such as the Haydom area in Tanzania (TZ), poor nutrition continues contributes to worsened health-related outcomes including growth and cognitive development. Haydom Global Health Research Center at Haydom Lutheran Hospital in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. Through ongoing work in the area around Haydom in the MAL-ED and ELICIT studies, we have been attempting to improve outcomes for children in an area of severe poverty, where there is considerable malnutrition and potential sequelae:
- Growth deficits: Poor weight gain and linear growth failure in childhood are often seen as surrogates for overall health status; persistently poor growth has implications for future work potential and lower human capital. There was a high degree of stunting in the Haydom site of Tanzanian in the multi-country observational MAL-ED study, which found that the Haydom site had the highest prevalence of stunting among all the MAL-ED sites. This degree of stunting is likely multi-factorial, though one contributor is food availability, as rates of key factors such as birthweight vary significantly according to food availability. An interim analysis of data from our ongoing ELICIT study (for Early Life Interventions for Childhood
Developmental delays: Perhaps there is no more important outcome (with the exception of mortality) than the cognitive, social and emotional development of a population, with clear extensions to human capital, economic productivity and quality of life in communities. Indeed, many observational and interventional studies (including the current study) follow growth as an outcome because of its overall association with cognitive development. In MAL-ED assessments, TZ children had fewer words than seen among US children. The reasons for potential developmental delays are multifactorial, but again malnutrition may play an important role. Studies in other developing areas have demonstrated improved cognitive development following delivery of nutrition support.
Nutritional Causes of Poor Growth
While the causes of the stunting and developmental delays are multifactorial, a potential contributor is early-life nutritional deficiencies, including inadequate dietary protein. One likely source of low protein delivery to infants is from low intake among area mothers during lactation, with potential effects on breast milk protein content and child weight gain. Indeed, the first six months of life represents a critical phase of nutrition for the developing infant, in which all (or nearly all) nutrition is delivered through the mother's breast milk. However, it is not known whether protein supplementation during lactation in this setting would improve childhood growth and reduce stunting-or whether any improvements in growth would continue beyond the period of maternal supplementation.
Assessing the potential effect of mothers receiving protein supplementation-using a balanced energy protein supplement-on childhood growth and development would require an approach that incorporates an effective distribution network, a means of assessing adherence, and a thorough knowledge of community acceptance, as well as accurate measures of endpoints on a large enough sample to be powered to detect reasonable changes in linear growth. In order to assess the feasibility of this type of approach on a smaller scale (which could be later be expanded), the current pilot project will evaluate the effectiveness of distribution and adherence on approximately 100 mother/child dyads. If this experimental approach is feasible and shows promise, it is our hope to follow it with a larger study that offers more definitive evidence of efficacy.
- Conditions
- Growth Failure, Stunting, Malnutrition, Protein Malnutrition
- Being tested
- Plumpy'Mum
- Keywords
- protein, breast feeding, eggs, Ready-to-eat food, infant, growth, Tanzania
- Medical subject headings
- Failure to Thrive, Growth Disorders, Malnutrition, Kwashiorkor, Breast Feeding
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Plumpy'MumDietary supplement
Mothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months.
| Study group | Role | What they receive |
|---|---|---|
| Plumpy'Mum | Experimental | Mother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area. Receives: Dietary Supplement: Plumpy'Mum |
What is being measured
The primary outcome is the main question the study is designed to answer.
Family perception of Plumpy'Mum
Families will be queried about their impression of Plumpy'Mum
Measured: at 3 months after enrollment
Secondary outcomes (7)
Child weight-for-age Z-score (WAZ) after 3 months of Plumpy'Mum use
Child weight for WHO Z-score after 3 months of Plumpy'Mum use compared to historical controls
Measured: 3 months
Child head circumference-for-age Z-score (HCZ) after 3 months of Plumpy'Mum use
Child head circumference for WHO Z-score after 3 months of Plumpy'Mum use compared to historical controls
Measured: 3 months
Child mid-upper arm circumference-for-age Z-score (MUAC-Z) after 3 months of Plumpy'Mum use
Child mid-upper arm circumference Z-score after 3 months of Plumpy'Mum use compared to historical controls
Measured: 3 months
Child length-for-age Z-score (LAZ) after 3 months of Plumpy'Mum use
Child length for WHO Z-score after 3 months of Plumpy'Mum use compared to historical controls
Measured: 3 months
Adverse events
Number of adverse events in intervention arm, compared to historical controls
Measured: 3 months
Maternal weight at 3 months
Maternal weight at 3 months compared to historical controls
Measured: 3 months
Maternal mid-upper arm circumference-for-age Z-score (MUAC) at 3 months
Maternal mid-upper arm circumference at 3 months compared to historical controls
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2020
- Study start12 Nov 2019
- Primary completion31 Mar 2022 (estimated)
- Study completion1 Aug 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Growth FailureStudies of the same condition, open and under way.
- More trials run by University of VirginiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Participating mothers nursing children age 0-3 months at enrollment will receive 3 months of treatment with one packet of Plumpy'Mum.
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Virginia
- Sponsor type
- University, hospital or other
- Collaborators
- Haydom Lutheran Hospital, Bill and Melinda Gates Foundation
- Responsible party
- Principal investigator, Mark D. DeBoer, MD, MSc., MCR, University of Virginia
- Investigators
- Mark D DeBoer, MD, MSc, MCR, Principal investigator, University of Virginia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04565314
- Sponsor's protocol ID
- 21967
- Status last verified
- Feb 2021
- First submitted
- 22 Sep 2020
- Last updated
- 26 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will assess platforms for sharing individual participant data following final data analysis.
Study at a glance
From the registry record, last updated by the sponsor on 26 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ELICIT 2.0: Pilot Study of the Effect of Maternal Protein Supplementation During Lactation on Childhood Growth
- ClinicalTrials.gov ID
- NCT04565314
- Acronym / sponsor ID
- 21967
- Conditions
- Growth Failure, Stunting, Malnutrition, Protein Malnutrition
- Keywords
- protein, breast feeding, eggs, Ready-to-eat food, infant, growth, Tanzania
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of VirginiaUniversity, hospital or other
- Collaborators
- Haydom Lutheran Hospital, Bill and Melinda Gates Foundation
- Study start
- 12 Nov 2019 (actual)
- Primary completion
- 31 Mar 2022 (estimated)
- Study completion
- 1 Aug 2022 (estimated)
- First posted
- 25 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Haydom Global Health Research Center in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. The region around Haydom is agricultural (predominantly maize-based), is resource-poor and has a high degree of stunting among local infants-with 70% stunting by 18 months in the MAL-ED study and 50% in the ELICIT study (for Early Life Interventions for Childhood Growth and Development In Tanzania). While the causes of this stunting are multifactorial, a potential contributor is early-life nutritional deficiencies, including inadequate dietary protein.
One likely source of low protein delivery to infants is from low intake among area mothers during lactation, with potential effects on breast milk protein content and child weight gain. The current study is a pilot study assessing our study team's ability to successfully deliver protein-containing food products (a balanced-energy protein supplement) to lactating mother is in the area and assessing whether consumption of these food products improves childhood growth in the 1st year of life. This is a pilot study because of the potential difficulties in distributing these products on a large scale for daily consumption. As such, we aim to demonstrate an effective distribution network, a means of assessing adherence, and measuring endpoints while gathering knowledge regarding community acceptance. The current pilot project will evaluate the effectiveness of distribution and adherence on approximately 100 mother/child dyads. If effective, a future project could involve a large enough sample to be powered to detect reasonable changes in linear growth. .
So, while the current proposal is not adequately powered to prove a hypothesis, the hypothesis underlying the study design is that daily protein supplementation delivered as a balanced protein product (Plumpy'mum) to lactating mothers for 3 months during the period from 0-6 months post-natal life will result in an increase in infant length-for-age Z-score (LAZ) by end of treatment. LAZ will be compared to controls from prior studies in the area.
Detailed description
In severely under-resourced areas of the world, such as the Haydom area in Tanzania (TZ), poor nutrition continues contributes to worsened health-related outcomes including growth and cognitive development. Haydom Global Health Research Center at Haydom Lutheran Hospital in north central Tanzania represents an important rural setting for performing high-quality medical research in sub-Saharan Africa. Through ongoing work in the area around Haydom in the MAL-ED and ELICIT studies, we have been attempting to improve outcomes for children in an area of severe poverty, where there is considerable malnutrition and potential sequelae:
- Growth deficits: Poor weight gain and linear growth failure in childhood are often seen as surrogates for overall health status; persistently poor growth has implications for future work potential and lower human capital. There was a high degree of stunting in the Haydom site of Tanzanian in the multi-country observational MAL-ED study, which found that the Haydom site had the highest prevalence of stunting among all the MAL-ED sites. This degree of stunting is likely multi-factorial, though one contributor is food availability, as rates of key factors such as birthweight vary significantly according to food availability. An interim analysis of data from our ongoing ELICIT study (for Early Life Interventions for Childhood
Developmental delays: Perhaps there is no more important outcome (with the exception of mortality) than the cognitive, social and emotional development of a population, with clear extensions to human capital, economic productivity and quality of life in communities. Indeed, many observational and interventional studies (including the current study) follow growth as an outcome because of its overall association with cognitive development. In MAL-ED assessments, TZ children had fewer words than seen among US children. The reasons for potential developmental delays are multifactorial, but again malnutrition may play an important role. Studies in other developing areas have demonstrated improved cognitive development following delivery of nutrition support.
Nutritional Causes of Poor Growth
While the causes of the stunting and developmental delays are multifactorial, a potential contributor is early-life nutritional deficiencies, including inadequate dietary protein. One likely source of low protein delivery to infants is from low intake among area mothers during lactation, with potential effects on breast milk protein content and child weight gain. Indeed, the first six months of life represents a critical phase of nutrition for the developing infant, in which all (or nearly all) nutrition is delivered through the mother's breast milk. However, it is not known whether protein supplementation during lactation in this setting would improve childhood growth and reduce stunting-or whether any improvements in growth would continue beyond the period of maternal supplementation.
Assessing the potential effect of mothers receiving protein supplementation-using a balanced energy protein supplement-on childhood growth and development would require an approach that incorporates an effective distribution network, a means of assessing adherence, and a thorough knowledge of community acceptance, as well as accurate measures of endpoints on a large enough sample to be powered to detect reasonable changes in linear growth. In order to assess the feasibility of this type of approach on a smaller scale (which could be later be expanded), the current pilot project will evaluate the effectiveness of distribution and adherence on approximately 100 mother/child dyads. If this experimental approach is feasible and shows promise, it is our hope to follow it with a larger study that offers more definitive evidence of efficacy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Participating mothers nursing children age 0-3 months at enrollment will receive 3 months of treatment with one packet of Plumpy'Mum.
| Arm | Type | Receives |
|---|---|---|
| Plumpy'Mum | Experimental | Dietary Supplement: Plumpy'MumMother/child dyads will be enrolled at child age 0-3 months and mothers will immediately begin consuming a packet of Plumpy'Mum (or similar protein food product) daily. Plumpy'Mum will be provided by the study team to the mother, who will consume this however she desires (i.e., alone or with other food). Intervention will continue for 3 months. The rational is that Plumpy'Mum consumption will improve the quality of the breast milk the child is consuming, contributing to improved growth over time. Growth will be compared to historical controls from prior studies in the area. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Maternal age >/= 18 years
- Current pregnancy or infant </= 3 months
Key exclusion criteria (5 listed)
- Maternal inability to adhere to protocol
- Multiple gestation
- Significant birth defect
- Maternal allergy to peanut, milk or soy
- Lack of breast feeding at enrollment (and lack of intention to continue breast feeding at time of enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Plumpy'MumMothers will consume Plumpy'Mum (one packet daily) from enrollment (child age 0-3 months) for 3 months. | Dietary supplement | Plumpy'Mum |
Primary outcome
Family perception of Plumpy'Mum
Time frame: at 3 months after enrollment
Families will be queried about their impression of Plumpy'Mum
7 secondary outcomes
Child weight-for-age Z-score (WAZ) after 3 months of Plumpy'Mum use
Time frame: 3 months
Child head circumference-for-age Z-score (HCZ) after 3 months of Plumpy'Mum use
Time frame: 3 months
Child mid-upper arm circumference-for-age Z-score (MUAC-Z) after 3 months of Plumpy'Mum use
Time frame: 3 months
Child length-for-age Z-score (LAZ) after 3 months of Plumpy'Mum use
Time frame: 3 months
Adverse events
Time frame: 3 months
Maternal weight at 3 months
Time frame: 3 months
Maternal mid-upper arm circumference-for-age Z-score (MUAC) at 3 months
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Feb 2021.
- Individual participant dataSharing planned: Yes. We will assess platforms for sharing individual participant data following final data analysis.
Related trials for Growth Failure
RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Turner Syndrome, Short Stature Homeobox Gene Mutation
Active, not recruitingPhase 3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
Advanced or Metastatic NSCLC
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 3
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
Growth Disorders, Growth Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mark D DeBoer, MD, MSc, MCR principal investigator
University of Virginia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Plumpy'Mum in people with Growth Failure and Stunting, run by University of Virginia at 1 site in Tanzania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Tanzania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Family perception of Plumpy'Mum (time frame: at 3 months after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Feb 2021.